AQST

Company Overview — What Does Aquestive Therapeutics, Inc. Do?

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. Aquestive Therapeutics, Inc. (AQST) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel Barber and employs approximately 160 people. With a market capitalization of $504M, AQST is one of the notable companies in the Healthcare sector.

Aquestive Therapeutics, Inc. (AQST) Stock Rating — Reduce (April 2026)

As of April 2026, Aquestive Therapeutics, Inc. receives a Reduce rating with a composite score of 31.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AQST ranks #2,878 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aquestive Therapeutics, Inc. ranks #403 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AQST Stock Price and 52-Week Range

Aquestive Therapeutics, Inc. (AQST) currently trades at $4.05. The stock lost $0.12 (2.9%) in the most recent trading session. The 52-week high for AQST is $7.55, which means the stock is currently trading -46.4% from its annual peak. The 52-week low is $2.12, putting the stock 91.0% above its annual trough. Recent trading volume was 996K shares, suggesting relatively thin trading activity.

Is AQST Overvalued or Undervalued? — Valuation Analysis

Aquestive Therapeutics, Inc. (AQST) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 11.18x, compared to 1.66x for the average Healthcare stock.

At current multiples, Aquestive Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aquestive Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Aquestive Therapeutics, Inc. (AQST) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -39.5% versus the sector average of -33.1%.

On a margin basis, Aquestive Therapeutics, Inc. reports gross margins of 61.1%, compared to 71.5% for the sector. The operating margin is -121.6% (sector: -66.1%). Net profit margin stands at -151.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -36.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AQST Debt, Balance Sheet, and Financial Health

Balance sheet data for AQST is evaluated through our stability factor. The current ratio is 3.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $45M. Cash and equivalents stand at $129M.

AQST has a beta of 1.17, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Aquestive Therapeutics, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aquestive Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aquestive Therapeutics, Inc. reported revenue of $45M and earnings per share (EPS) of $-0.78. Net income for the quarter was $-63M. Gross margin was 61.1%. Operating income came in at $-51M.

In FY 2025, Aquestive Therapeutics, Inc. reported revenue of $45M and earnings per share (EPS) of $-0.78. Net income for the quarter was $-84M. Gross margin was 58.4%. Revenue grew -22.6% year-over-year compared to FY 2024. Operating income came in at $-71M.

In Q3 2025, Aquestive Therapeutics, Inc. reported revenue of $13M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-15M. Gross margin was 64.8%. Revenue grew -5.4% year-over-year compared to Q3 2024. Operating income came in at $-11M.

In Q2 2025, Aquestive Therapeutics, Inc. reported revenue of $10M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-14M. Gross margin was 54.4%. Revenue grew -50.2% year-over-year compared to Q2 2024. Operating income came in at $-11M.

Over the past 8 quarters, Aquestive Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $20M to $45M. Investors analyzing AQST stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AQST Dividend Yield and Income Analysis

Aquestive Therapeutics, Inc. (AQST) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AQST Momentum and Technical Analysis Profile

Aquestive Therapeutics, Inc. (AQST) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

AQST vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aquestive Therapeutics, Inc. (AQST) ranks #403 out of 838 stocks based on the Blank Capital composite score. This places AQST in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AQST against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AQST vs S&P 500 (SPY) comparison to assess how Aquestive Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

AQST Next Earnings Date

No upcoming earnings date has been announced for Aquestive Therapeutics, Inc. (AQST) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AQST? — Investment Thesis Summary

The quantitative profile for Aquestive Therapeutics, Inc. suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. High volatility (stability score 30/100) increases portfolio risk.

In summary, Aquestive Therapeutics, Inc. (AQST) earns a Reduce rating with a composite score of 31.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AQST stock.

Related Resources for AQST Investors

Explore more research and tools: AQST vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AQST head-to-head with peers: AQST vs AZN, AQST vs SLGL, AQST vs VMD.